期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

用药代动力学和药效学理论指导严重耐药菌感染时抗菌药物的合理应用 被引量：12

原文传递
导出
摘要 随着抗菌药物在临床的广泛应用,细菌耐药变得日益严重,尤其是多重耐药（multi-drug resistance,MDR）菌已经成为重症感染患者治疗失败的重要原因,尤其是近年来广泛耐药（extensive drug resistance,XDR）菌和全耐药（pan-drug resistance,PDR）菌的分离率不断增加,如耐甲氧西林金黄色葡萄球菌（MRSA）、广泛耐药非发酵菌（铜绿假单胞菌和鲍曼不动杆菌）、产超广谱β-内酰胺酶（ESBL）肠杆菌科细菌（肺炎克雷伯菌和大肠埃希菌）及产碳青霉烯酶肠杆菌科细菌[CRE,其中主要是产碳青霉烯酶肺炎克雷伯菌（KPC）],使临床治疗更为困难,其中不充分的抗菌药物暴露是耐药菌产生的重要原因.
作者 施毅 苏欣
机构地区 南京军区南京总医院呼吸与危重症医学科
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2015年第1期4-7,共4页 Chinese Journal of Tuberculosis and Respiratory Diseases
关键词 耐药菌感染 抗菌药物 合理应用 药代动力学 耐甲氧西林金黄色葡萄球菌 产超广谱Β-内酰胺酶 药效学 肠杆菌科细菌
分类号 R446.5 [医药卫生—诊断学]
  • 相关文献

参考文献13

  • 1Theuretzbacher U.Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer[J].CID,2012,54(12):1785-1792.
  • 2肖永红.抗菌药物药代动力学/药效学与医院肺炎的优化治疗[J].实用医院临床杂志,2013,10(4):1-4. 被引量：14
  • 3陈勇川.PK/PD原理在多重耐药菌感染治疗中的应用[J].中国临床药学学术年会暨第九届临床药师论坛论文集,南昌,2013.中国医院协会药事管理专业委员会,2013.
  • 4Roberts JA,Abdul-Aziz MH,Lipman J,et al.Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions[J].Lancet Infect Dis,2014,14 (6):498-509.
  • 5Goulenok T,Fantin B.Antimicrobial treatment of febrile neutropenia:pharmacokinetic-pharmacodynamic considerations[J].Clin Pharmacokinet,2013,52(10):869-883.
  • 6Zavascki AP,Bulitta JB,Landersdorfer CB.Combination therapy for carbapenem resistant gram-negative bacteria[J].Anti Infect Ther,2013,11 (12):1333-1353.
  • 7Falagas ME,Rafailidis PI,Ioannidou E,et al.Colistin therapy for microbiologically documented multidrug-resistant Gramnegative bacterial infections:a retrospective cohort study of 258patients[J].Int J Antimicrob Agents,2010,35 (2):194-199.
  • 8Dalfino L,Puntillo F,Mosca A,et al.High-dose,extendedinterval colistin administration in critically ill patients:is this the right dosing strategy? A preliminary study[J].Clin Infect Dis,2012,54(12):1720-1726.
  • 9Vicari G,Bauer SR,Neuner EA,et al.Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia[J].Clin Infect Dis,2013,56(3):398-404.
  • 10Deryke CA,Crawford AJ,Uddin N,et al.Colistin dosing and nephrotoxicity in a large community teaching hospital[J].Antimicrob Agents Chemother,2010,54(10):4503-4505.

二级参考文献15

  • 1肖永红.抗菌药物的药代动力学/药效学概念及其临床意义[J].中华医学杂志,2004,84(22):1914-1915. 被引量：36
  • 2肖永红.临床抗菌药物学[M].重庆:重庆出版社,2004:129.
  • 3Eagle I-I, Fleishman R, Musselman A. Effect of schedule of adminis- tration on the therapeutic efficacy of penicillin [ J ]. Am J Med, 1950, 9:280-299.
  • 4Craig WA. pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men [ J ]. Clin Infect Dis, 1998, 26:1-6.
  • 5Koomanachai P, Bulik CC, Kuti JL, et al. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States[ J]. Clin Ther,2010,32(4) :766-779.
  • 6American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, vent- ilator-acquired and healthcare-associated pneumonia [ J ]. Am J Re- spir Crit Care Med,2005,171:388-416.
  • 7Frimodt-Moller N. How predictive is PK/PD for antibacterial agents [ J ]. Int J Antimicrob Agents,2002,19 : 333-339.
  • 8Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: A new paradigm for early chnical trials[J]. J Am Med Assoc, 1998,279 : 125-129.
  • 9Ambrose PG, Quintiliani R, Nightingale CH, et al. Continuous vs in- termittent infusion of cefuroxime for the treatment of community ac- quired pneumonia [ J ]. Infect Dis Clin Prac, 1998,7 : 463-470.
  • 10Forrest A,Nix DE,Ballow CH,et al. Pharmacodynamics of intravenous ciproiloxacin in seriously ill patients[ J ]. Antimicrob Agent Chemother, 1993,37 : 1073-1081.

共引文献13

同被引文献118

  • 1张晓峰.中老年人医院常用抗菌药物说明书用药表述的调查[J].中国老年学杂志,2014,34(10):2843-2844. 被引量：2
  • 2顾正平,朱亚虹,陆惠平.头孢哌酮致不良反应454例文献分析[J].医药导报,2007,26(2):204-205. 被引量：21
  • 3中国药典.二部[S].2010:凡例ⅩⅦ.
  • 4中国医药教育协会感染疾病专业委员会,中华结核和呼吸杂志编辑委员会,中国药学会药物临床评价研究专业委员会.抗菌药物超说明书用法专家共识[J].中华结核和呼吸杂志,2015,38:410-444.
  • 5NARAWADEENIAMHUN, PANOMVANA D, PONGPECHP, et al. Pharmacodynamic target associated with clinicaloutcome of hospital-acquired pneumonia treatment withefoperazone/sulbactam [J]. Int J Pharm Pharm Sci, 2012,4(Suppl 1): 584-589.
  • 6SIPAHI O R, ARDA B,NAZLI-ZEKA A,et al. Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-riskfebrile neutropenia cases [J]. Int J Clin Pract, 2014, 68(2):230-235.
  • 7WANG Q, WU Y X, CHEN B Y, et al. Drug concentrations inthe serum and cerebrospinal fluid of patients treated withcefoperazone/sulbactam after craniotomy [J]. BMCAnesthesiol, 2015(15): 33. Doi: 10.1186/sl2871-015-0012-l.
  • 8周颖杰,王明贵,张婴元,等.头孢哌酮-舒巴坦(2 : 1)治疗多重耐药鲍曼不动杆菌医院获得性肺炎成人患者的药动学/药效学研宄[C].//中华医学会第三届感染与抗微生物治疗论坛、第九届全国感染性疾病及抗微生物化疗学术会议、第一届上海国际临床微生物及抗微生物化疗学术会议论文集.上海:2011:377-381.
  • 9M100-S20, CLSI [S]. 2014: 41-42, 47; M100-S23, CLSI [S].2014: 45-46,51.
  • 10SCHWARTZ J I,JAUREGUI L E, BACHMANN K A, et al.Multiple-close pharmacokinetics of intravenously administeredcefoperazone and sulbactam when given in combination toinfected, seriously ill, elderly patients [J]. Antimicrob AgentsChemother, 1988,32(5): 730-735.

引证文献12

二级引证文献75

中华结核和呼吸杂志
2015年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部